Comprehensive Stock Comparison
Compare Precision BioSciences, Inc. (DTIL) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs DTIL's 41.0% |
| Quality / Margins | AGIO | -9.0% net margin vs DTIL's -119.8% |
| Stability / Safety | DTIL | Beta 0.66 vs AGIO's 0.91 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | AGIO | -14.9% vs DTIL's -22.1% |
| Efficiency (ROA) | AGIO | -29.0% ROA vs DTIL's -89.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Precision BioSciences is a clinical-stage biotechnology company developing gene editing therapies using its proprietary ARCUS platform. It generates revenue primarily through research collaborations and licensing deals with pharmaceutical partners — like its Servier partnership for CAR-T therapies — while advancing its own pipeline of in vivo gene editing and allogeneic CAR-T candidates. The company's key advantage is its ARCUS genome editing technology, which offers precise DNA cutting with potentially lower off-target effects than other gene editing approaches.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AGIO leads in 2 of 6 categories (Financial Metrics, Total Returns). DTIL leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Financial Metrics (TTM)
AGIO is the larger business by revenue, generating $45M annually — 64.2x DTIL's $698,000. AGIO is the more profitable business, keeping -9.0% of every revenue dollar as net income compared to DTIL's -119.8%. On growth, AGIO holds the edge at +43.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DTILPrecision BioScie… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $698,000 | $45M |
| EBITDAEarnings before interest/tax | -$87M | -$470M |
| Net IncomeAfter-tax profit | -$84M | -$401M |
| Free Cash FlowCash after capex | -$74M | -$414M |
| Gross MarginGross profit ÷ Revenue | -96.3% | +84.4% |
| Operating MarginEBIT ÷ Revenue | -128.2% | -10.6% |
| Net MarginNet income ÷ Revenue | -119.8% | -9.0% |
| FCF MarginFCF ÷ Revenue | -105.6% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -97.7% | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +18.1% | -111.0% |
Valuation Metrics
| Metric | DTILPrecision BioScie… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $51M | $2.25T |
| Enterprise ValueMkt cap + debt − cash | -$5M | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 4.04x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.74x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 0.51x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AGIO delivers a -31.2% return on equity — every $100 of shareholder capital generates $-31 in annual profit, vs $-5 for DTIL. AGIO carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to DTIL's 0.53x. On the Piotroski fundamental quality scale (0–9), DTIL scores 4/9 vs AGIO's 3/9, reflecting mixed financial health.
| Metric | DTILPrecision BioScie… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -5.0% | -31.2% |
| ROA (TTM)Return on assets | -89.4% | -29.0% |
| ROICReturn on invested capital | — | -26.6% |
| ROCEReturn on capital employed | -22.6% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.53x | 0.03x |
| Net DebtTotal debt minus cash | -$56M | -$49M |
| Cash & Equiv.Liquid assets | $86M | $89M |
| Total DebtShort + long-term debt | $30M | $40M |
| Interest CoverageEBIT ÷ Interest expense | -56.03x | — |
Total Returns (with DRIP)
A $10,000 investment in AGIO five years ago would be worth $6,363 today (with dividends reinvested), compared to $109 for DTIL. Over the past 12 months, AGIO leads with a -14.9% total return vs DTIL's -22.1%. The 3-year compound annual growth rate (CAGR) favors AGIO at 6.1% vs DTIL's -50.0% — a key indicator of consistent wealth creation.
| Metric | DTILPrecision BioScie… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +2.4% | +11.2% |
| 1-Year ReturnPast 12 months | -22.1% | -14.9% |
| 3-Year ReturnCumulative with dividends | -87.5% | +19.4% |
| 5-Year ReturnCumulative with dividends | -98.9% | -36.4% |
| 10-Year ReturnCumulative with dividends | -99.2% | -21.2% |
| CAGR (3Y)Annualised 3-year return | -50.0% | +6.1% |
Risk & Volatility
DTIL is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs DTIL's 47.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DTILPrecision BioScie… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 0.91x |
| 52-Week HighHighest price in past year | $8.82 | $46.00 |
| 52-Week LowLowest price in past year | $3.53 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +47.6% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 49.8 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 197K | 948K |
Analyst Outlook
| Metric | DTILPrecision BioScie… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $41.50 |
| # AnalystsCovering analysts | — | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | 100 | 1.68 | -98.3% |
| Agios Pharmaceutica… (AGIO) | 100 | 57.07 | -42.9% |
Agios Pharmaceutica… (AGIO) returned -36% over 5 years vs Precision BioScienc… (DTIL)'s -99%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | $7M | $69M | +879.3% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | -117.6% | 10.4% | +108.9% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | -0.49 | 1.04 | +312.2% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 5Free Cash Flow — 5 Years
Precision BioSciences, Inc. generated $-59M FCF in 2024 (-252% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
DTIL vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is DTIL or AGIO a better buy right now?
Precision BioSciences, Inc. (DTIL) offers the better valuation at 4.0x trailing P/E, making it the more compelling value choice. Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DTIL or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc. (AGIO) delivered a total return of -36.4%, compared to -98.9% for Precision BioSciences, Inc. (DTIL). A $10,000 investment in AGIO five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AGIO returned -21.2% versus DTIL's -99.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DTIL or AGIO?
By beta (market sensitivity over 5 years), Precision BioSciences, Inc. (DTIL) is the lower-risk stock at 0.66β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 37% more volatile than DTIL relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 53% for Precision BioSciences, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — DTIL or AGIO?
Precision BioSciences, Inc. (DTIL) is the more profitable company, earning 10.4% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 10.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DTIL leads at -38.1% versus -873.9% for AGIO. At the gross margin level — before operating expenses — DTIL leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — DTIL or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is DTIL or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Precision BioSciences, Inc. (DTIL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.66)). Both have compounded well over 10 years (DTIL: -99.2%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between DTIL and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: DTIL is a small-cap deep-value stock; AGIO is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.